keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotic induced weight gain

keyword
https://www.readbyqxmd.com/read/28744755/resveratrol-protects-against-vacuous-chewing-movements-induced-by-chronic-treatment-with-fluphenazine
#1
Alcindo Busanello, Caroline Queiroz Leal, Luis Ricardo Peroza, Jivago Röpke, Elizete de Moraes Reis, Catiuscia Molz de Freitas, Milena Libardoni, Nilda Berenice de Vargas Barbosa, Roselei Fachinetto
Typical antipsychotics, which are commonly used to treat schizophrenia, cause motor disorders such as tardive dyskinesia (TD) in humans and orofacial dyskinesia (OD) in rodents. The disease mechanisms as well as treatment effectiveness are still unknown. In this study, we investigated the effect of resveratrol, a polyphenol with neuroprotective properties, on behavioral changes induced by chronic treatment with fluphenazine in rats and the possible relationship between monoamine oxidase (MAO) activity and vacuous chewing movements (VCMs)...
July 25, 2017: Neurochemical Research
https://www.readbyqxmd.com/read/28741044/efficacy-and-tolerability-of-asenapine-compared-with-olanzapine-in-borderline-personality-disorder-an-open-label-randomized-controlled-trial
#2
Paola Bozzatello, Paola Rocca, Maria Uscinska, Silvio Bellino
BACKGROUND: Asenapine is a new second-generation antipsychotic that is understudied in borderline personality disorder (BPD). Only one study investigating the use of the drug in this indication (an open-label pilot study) has been conducted to date. OBJECTIVE: The present open-label, randomized, controlled trial aimed to evaluate the efficacy and tolerability of asenapine in comparison with olanzapine, the most broadly studied antipsychotic in BPD. METHODS: A total of 51 outpatients aged between 18 and 50 years with a diagnosis of BPD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria were assigned for 12 weeks to asenapine (5-10 mg/day) or olanzapine (5-10 mg/day)...
July 24, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28718688/effect-of-adjunctive-ranitidine-for-antipsychotic-induced-weight-gain-a-systematic-review-of-randomized-placebo-controlled-trials
#3
Xiao-Jing Gu, Rui Chen, Chen-Hui Sun, Wei Zheng, Xin-Hu Yang, Shi-Bin Wang, Gabor S Ungvari, Chee H Ng, Andrei Golenkov, Grace K I Lok, Lu Li, Ines H I Chow, Fei Wang, Yu-Tao Xiang
This study was a meta-analysis of randomized controlled trials (RCTs) of ranitidine as an adjunct for antipsychotic-induced weight gain in patients with schizophrenia. RCTs reporting weight gain or metabolic side effects in patients with schizophrenia were included. Case reports/series, non-randomized or observational studies, reviews, and meta-analyses were excluded. The primary outcome measures were body mass index (BMI) (kg/m(2)) and body weight (kg). Four RCTs with five study arms were identified and analyzed...
January 1, 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28718324/physical-health-and-drug-safety-in-individuals-with-schizophrenia
#4
Tamara Pringsheim, Martina Kelly, Doug Urness, Michael Teehan, Zahinoor Ismail, David Gardner
BACKGROUND: While antipsychotic medications are the mainstay of therapy for individuals with schizophrenia and psychotic disorders, their use is associated with adverse effects on physical health that require the attention and care of prescribers. METHODS: We used the ADAPTE process to adapt existing guideline recommendations from the National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN) guidelines on the dosing of antipsychotics and antipsychotic polypharmacy, screening for adverse effects of antipsychotics, and management of metabolic and extrapyramidal side effects to the Canadian context...
January 1, 2017: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
https://www.readbyqxmd.com/read/28693754/a-comprehensive-analysis-of-mitochondrial-genes-variants-and-their-association-with-antipsychotic-induced-weight-gain
#5
Kirti Mittal, Vanessa F Gonçalves, Ricardo Harripaul, Ari B Cuperfain, Brandi Rollins, Arun K Tiwari, Clement C Zai, Malgorzata Maciukiewicz, Daniel J Müller, Marquis P Vawter, James L Kennedy
Antipsychotic Induced Weight Gain (AIWG) is a common and severe side effect of many antipsychotic medications. Mitochondria play a vital role for whole-body energy homeostasis and there is increasing evidence that antipsychotics modulate mitochondrial function. This study aimed to examine the role of variants in nuclear-encoded mitochondrial genes and the mitochondrial DNA (mtDNA) in conferring risk for AIWG. We selected 168 European-Caucasian individuals from the CATIE sample based upon meeting criteria of multiple weight measures while taking selected antipsychotics (risperidone, quetiapine or olanzapine)...
July 7, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28624847/the-microbiome-gut-brain-axis-implications-for-schizophrenia-and-antipsychotic-induced-weight-gain
#6
REVIEW
S Kanji, T M Fonseka, V S Marshe, V Sriretnakumar, M K Hahn, D J Müller
With the emergence of knowledge implicating the human gut microbiome in the development and regulation of several physiological systems, evidence has accumulated to suggest a role for the gut microbiome in psychiatric conditions and drug response. A complex relationship between the enteric nervous system, the gut microbiota and the central nervous system has been described which allows for the microbiota to influence and respond to a variety of behaviors and psychiatric conditions. Additionally, the use of pharmaceuticals may interact with and alter the microbiota to potentially contribute to adverse effects of the drug...
June 17, 2017: European Archives of Psychiatry and Clinical Neuroscience
https://www.readbyqxmd.com/read/28601891/effect-of-liraglutide-treatment-on-prediabetes-and-overweight-or-obesity-in-clozapine-or-olanzapine-treated-patients-with-schizophrenia-spectrum-disorder-a-randomized-clinical-trial
#7
RANDOMIZED CONTROLLED TRIAL
Julie R Larsen, Louise Vedtofte, Mathilde S L Jakobsen, Hans R Jespersen, Michelle I Jakobsen, Camilla K Svensson, Kamuran Koyuncu, Ole Schjerning, Peter S Oturai, Andreas Kjaer, Jimmi Nielsen, Jens J Holst, Claus T Ekstrøm, Christoph U Correll, Tina Vilsbøll, Anders Fink-Jensen
Importance: Compared with the general population, patients with schizophrenia have a 2- to 3-fold higher mortality rate primarily caused by cardiovascular disease. Previous interventions designed to counteract antipsychotic-induced weight gain and cardiometabolic disturbances reported limited effects. Objectives: To determine the effects of the glucagon-like peptide-1 receptor agonist liraglutide added to clozapine or olanzapine treatment of schizophrenia spectrum disorders...
July 1, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28595931/aripiprazole-induced-adverse-metabolic-alterations-in-polyi-c-neurodevelopmental-model-of-schizophrenia-in-rats
#8
Katerina Horska, Jana Ruda-Kucerova, Eva Drazanova, Michal Karpisek, Regina Demlova, Tomas Kasparek, Hana Kotolova
Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis...
September 1, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28586744/protective-effects-of-green-tea-on-olanzapine-induced-metabolic-syndrome-in-rats
#9
Bibi Marjan Razavi, Fariba Lookian, Hossein Hosseinzadeh
Atypical antipsychotics particularly olanzapine are associated with obesity and serious metabolic disturbances. As green tea (Camellia sinensis) is generally associated with beneficial effects on obesity and other metabolic disturbances, this study was undertaken to evaluate the effect of green tea aqueous extract (GTAE) on olanzapine induced weight gain and metabolic abnormalities in rats. Male Wistar rats were divided into eight groups: control, olanzapine (5mg/kg/day, IP.), GTAE (25, 50 and 100mg/kg/day, IP...
August 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28584269/time-dependent-changes-and-potential-mechanisms-of-glucose-lipid-metabolic-disorders-associated-with-chronic-clozapine-or-olanzapine-treatment-in-rats
#10
Xuemei Liu, Zhixiang Wu, Jiamei Lian, Chang-Hua Hu, Xu-Feng Huang, Chao Deng
Chronic treatment with second-generation antipsychotic drugs (SGAs) has been associated with an increased risk of metabolic syndrome. To evaluate the longitudinal changes in glucose-lipid homeostasis after SGA use, we studied the time-dependent effects of olanzapine (OLZ) (3 mg/kg, b.i.d.) or clozapine (CLZ) (20 mg/kg, b.i.d.) treatment on metabolic profiles for 9 weeks in rats. Although only OLZ significantly increased body weight in rats, both OLZ and CLZ elevated blood lipid levels. Chronic OLZ treatment induced significant weight gain leading to a higher fasting insulin level and impaired glucose tolerance, whereas CLZ lowered fasting insulin levels and impaired glucose tolerance independent of weight gain...
June 5, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28579786/topiramate-add-on-treatment-associated-with-normalization-of-prolactin-levels-in-a-patient-with-schizophrenia
#11
Yinglin Huang, Huan Ma, Yuan Wang, Miao Peng, Gang Zhu
Topiramate has been used increasingly in the management of psychiatric conditions. Clinical trials demonstrated that topiramate augmentation was effective in controlling negative symptoms in schizophrenia. This case report presents a case of a 38-year-old man with schizophrenia who achieved full negative symptom remission upon the adjunctive use of topiramate. However, the remarkable finding of this case is the concomitant decrease in the level of prolactin when topiramate (50 mg/day) was started and the rebound after discontinuation of topiramate...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28560263/dopamine-d2-receptors-and-the-circadian-clock-reciprocally-mediate-antipsychotic-drug-induced-metabolic-disturbances
#12
Zachary Freyberg, Michael J McCarthy
Antipsychotic drugs are widely prescribed medications, used for numerous psychiatric illnesses. However, antipsychotic drugs cause serious metabolic side effects that can lead to substantial weight gain and increased risk for type 2 diabetes. While individual drugs differ, all antipsychotic drugs may cause these important side effects to varying degrees. Given that the single unifying property shared by these medications is blockade of dopamine D2 and D3 receptors, these receptors likely play a role in antipsychotic drug-induced metabolic side effects...
2017: NPJ Schizophrenia
https://www.readbyqxmd.com/read/28540050/effect-of-atypical-antipsychotics-on-body-weight-in-geriatric-psychiatric-inpatients
#13
Eugene Yh Yeung, Soojin Chun, Alan Douglass, Timothy E Lau
BACKGROUND: Studies suggest that antipsychotic-induced weight gain is not a great concern in the elderly population. This study investigated the weight change in elderly patients with various treatment duration and antipsychotics. Part 1 of the study was to determine whether atypical antipsychotics induced weight change in elderly patients. Part 2 was to determine whether certain atypical antipsychotics induced more weight change in elderly patients. METHODS: In Part 1, a retrospective chart review was done on 115 geriatric inpatients...
2017: SAGE Open Medicine
https://www.readbyqxmd.com/read/28531893/association-study-of-serotonin-3-receptor-subunit-gene-variants-in-antipsychotic-induced-weight-gain
#14
Clement C Zai, Arun K Tiwari, Nabilah I Chowdhury, Eva J Brandl, Sajid A Shaikh, Natalie Freeman, Jeffrey A Lieberman, Herbert Y Meltzer, James L Kennedy, Daniel J Müller
BACKGROUND: Schizophrenia (SCZ) is a chronic severe neuropsychiatric disorder, where pharmacological treatment has been hindered by adverse effects, including antipsychotic-induced weight gain (AIWG) and related complications. Genetic studies have been exploring the appetite regulation and energy homeostasis pathways in AIWG with some promising leads. The serotonin system has been shown to participate in these pathways. METHODS: In the current study, we examined single nucleotide polymorphisms across the serotonin receptor genes HTR3A and HTR3B...
2016: Neuropsychobiology
https://www.readbyqxmd.com/read/28507773/rapid-onset-clozapine-induced-loss-of-glycaemic-control-case-report
#15
Alejandro Porras-Segovia, Amir Krivoy, Mark Horowitz, George Thomas, Mark Bolstridge, Dragos Ion, Sukhwinder S Shergill
Clozapine has proved to be an effective antipsychotic for the treatment of refractory schizophrenia - characterised by the persistence of symptoms despite optimal treatment trials with at least two different antipsychotics at adequate dose and duration - but its use is hampered by adverse effects. The development of clozapine-induced diabetes is commonly considered to arise as part of a metabolic syndrome, associated with weight gain, and thus evolves slowly. We present the case of an individual with refractory schizophrenia and metformin-controlled diabetes who developed rapid-onset insulin-dependent hyperglycaemia immediately after starting clozapine...
May 2017: BJPsych Open
https://www.readbyqxmd.com/read/28463344/minimizing-weight-gain-for-patients-taking-antipsychotic-medications-the-potential-role-for-early-use-of-metformin
#16
Victoria Hendrick, Robert Dasher, Michael Gitlin, Mehrban Parsi
BACKGROUND: Patients taking antipsychotic medications are at high risk for weight gain, which in turn leads to poor health outcomes, nonadherence with treatment, and low self-esteem. METHODS: We reviewed published studies of pharmacologic interventions aimed at minimizing antipsychotic-induced weight gain. Treatments initiated prior to onset of weight gain were compared with those that started once weight gain already had occurred. RESULTS: Although data are limited, adjunctive medications for weight management appear to be more effective when initiated at or near the time when patients are first exposed to antipsychotic medications...
May 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/28453334/different-immune-signature-in-youths-experiencing-antipsychotic-induced-weight-gain-compared-to-untreated-obese-patients
#17
Simone Pisano, Gennaro Catone, Giangennaro Coppola, Marco Carotenuto, Raffaella Iuliano, Claudia Tiano, Anna Rita Montesanto, Vittoria D'Esposito, Emanuele Miraglia Del Giudice, Pietro Formisano, Carmela Bravaccio
OBJECTIVES: To assess cytokine and chemokine levels in youth experiencing antipsychotic-induced weight gain (AIWG) compared to obese patients, hypothesizing a different "immune signature" between the two kinds of obesity. METHODS: We compared a group of youth experiencing AIWG (N 19, mean age 159 months, mean body mass index [BMI] z-score 1.81) and an age-, gender-, and BMI-matched group of untreated obese patients (N 19, mean age 147 months, mean BMI z-score 2) for a wide range of cytokines and chemokines by using a multiplex ELISA test...
April 28, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28447303/brief-report-metformin-for-antipsychotic-induced-weight-gain-in-youth-with-autism-spectrum-disorder
#18
Logan K Wink, Ryan Adams, Ernest V Pedapati, Kelli C Dominick, Emma Fox, Catherine Buck, Craig A Erickson
Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD...
July 2017: Journal of Autism and Developmental Disorders
https://www.readbyqxmd.com/read/28408348/design-and-in-vivo-evaluation-of-solid-lipid-nanoparticulate-systems-of-olanzapine-for-acute-phase-schizophrenia-treatment-investigations-on-antipsychotic-potential-and-adverse-effects
#19
Emil Joseph, Satish Reddi, Vibhu Rinwa, Garima Balwani, Ranendra Saha
The present paper discusses the design, characterization and in vivo evaluation of glyceryl monostearate nanoparticles of Olanzapine, an atypical antipsychotic drug for acute schizophrenia treatment, during which hospitalization is mandatory and adverse effects are at its peak. The solid lipid nanoparticulate system was obtained by emulsification-ultra sonication technique wherein three factors such as solid lipid content, concentration of surfactant and drug: solid lipid ratio were selected at three different levels in order to study their influence on significant characteristic responses such as particle size, encapsulation efficiency and drug content...
June 15, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28400260/prevention-of-the-adverse-effects-of-olanzapine-on-lipid-metabolism-with-the-antiepileptic-zonisamide
#20
Aneta Stefanidis, Matthew J Watt, Michael A Cowley, Brian J Oldfield
BACKGROUND: Atypical antipsychotic drugs, particularly olanzapine, represent a mainstay in the treatment of psychoses; however, their use is commonly associated with weight gain and diabetes. The aim of this study was to determine whether combined administration of olanzapine and zonisamide can be used to prevent olanzapine-induced metabolic disturbances. METHODS AND RESULTS: These experiments involved female Sprague Dawley rats (n = 6-8/group) that were administered olanzapine, either acutely (6 mg/kg, s...
April 8, 2017: Neuropharmacology
keyword
keyword
99026
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"